selank

This study examined Selank and GABA effects on mRNA expression of 84 neurotransmission-related genes in rat frontal cortex following intranasal administration. Among 77 analyzed genes, 45 showed expression changes at 1-hour post-administration. Twenty-five genes responded to both Selank and GABA, including GABA receptor subunits (Gabrb3, Gabre, Gabrq), dopamine receptors (Drd3, Drd5), serotonin receptor (Htr3a), and calcium channels (Cacna1a, Cacna1b). Results demonstrated Selank's complex multi-system effects beyond simple GABAergic modulation, with allosteric GABA-A receptor modulation as one molecular mechanism. Gene expression similarity between Selank and GABA supported their mechanistic overlap despite Selank's lack of direct receptor binding.

Researchers evaluated Selank and diazepam anxiolytic activity individually and combined in rats under unpredictable chronic mild stress using elevated plus maze testing. Under chronic stress conditions, simultaneous Selank and diazepam administration normalized anxiety indicators to pre-stress baseline levels—effects neither compound achieved alone. Results demonstrated Selank amplifies diazepam anxiolytic action, suggesting Selank not only allosterically modulates GABA-A receptors but also increases diazepam affinity to these receptors. Combined administration potential allows benzodiazepine dose reduction, minimizing side effects while maintaining therapeutic efficacy. Study confirmed Selank's anxiolytic potency comparable to classical benzodiazepines with potentially similar GABAergic action mechanisms.

This study compared Selank (300 μg/kg) effects with piracetam (400 mg/kg) on learning and memory in rats with initially poor learning ability using conditioned active avoidance reflex paradigm. Selank significantly activated learning processes in poor-performing rats with effects apparent after first dose on training day 1. Progressive improvement occurred with repeated administration—total correct solutions increased while errors decreased (p<0.05). Maximum optimizing activity in normal rats appeared on day 3 after initial consolidation phase formation. Dynamic features of Selank and piracetam activating actions were characterized, with Selank showing potential for optimizing mnestic functions under elevated emotional tension conditions, combining anxiolytic with nootropic properties.

This clinical trial compared Selank (30 patients) with medazepam (32 patients) in treating 62 generalized anxiety disorder and neurasthenia patients. Patient state assessments used Hamilton Anxiety Rating Scale, Zung Self-Rating Scale, and CGI. Anxiolytic effects of both drugs were similar, but Selank additionally demonstrated antiasthenic and psychostimulant effects absent with medazepam. Clinical-biological analysis revealed GAD and neurasthenia patients had decreased leu-enkephalin tau½ levels correlating with disease duration, anxiety symptom severity, asthenia, and autonomic disorders. Selank treatment increased this parameter with stronger positive anxiety correlations, particularly in GAD patients. Results supported Selank's dual anxiolytic-cognitive enhancement profile with favorable enkephalin system modulation compared to traditional benzodiazepines.

Researchers analyzed Selank effects on memory impairment and BDNF content in brain structures of outbred rats receiving 10% ethanol as sole fluid source for 30 weeks. In object recognition testing, Selank (0.3 mg/kg/day, 7 days intraperitoneally) produced cognitive-stimulating effects in 9-month rats without ethanol exposure (p<0.05) and prevented ethanol-induced memory and attention disturbances developing during alcohol withdrawal (p<0.01). Ex vivo experiments showed Selank prevented ethanol-induced BDNF content increases in hippocampus and frontal cortex (p<0.05). Results indicated positive tuftsin analogue effects on age-related memory disturbances associated with chronic alcohol intoxication, confirming neurotrophin BDNF production involvement in Selank's mechanism of action.

Examination of anxiety and phobic disorder patients (DSM-4 criteria) demonstrated considerable enkephalin half-life shortening and reduced total enkephalinase activity during generalized anxiety, but not panic disorders or agoraphobia—probably related to low endogenous inhibitor concentrations in GAD patients. Heptapeptide Selank dose-dependently inhibited plasma enkephalin enzymatic hydrolysis (IC50 15 μM) more potently than peptidase inhibitors bacitracin and puromycin. Results suggested Selank's high efficiency in anxiety and phobic disorder therapy, including generalized anxiety, stems from its enkephalin hydrolysis inhibition ability. This mechanism explains Selank's anxiolytic effects without typical anxiolytic side effects through endogenous opioid system potentiation rather than direct receptor agonism.

This study examined Selank glyprolin neuropeptide drug effects on cytokine levels in rats under "social" stress conditions using male confrontation model. White nonlinear rats were divided into three groups: intact males, 20-day stress-exposed animals, and animals receiving intraperitoneal Selank (100 μg/kg/day) under 20-day stress. ELISA determination revealed stress-exposed animals showed statistically significant IL-1β, IL-6, and TGF-β1 increases in both behavioral phenotypes. Selank administration reduced these pro-inflammatory (IL-1β, IL-6, TNF-α) and anti-inflammatory (TGF-β1) cytokine concentrations to near-control values, indicating stress-protective activity. Results demonstrated Selank's immunomodulatory properties extend to stress-induced inflammatory responses with potential neuroinflammation mitigation applications.

Researchers studied Selank effects on acute 48-hour alcohol withdrawal symptom development in outbred rats drinking 10% ethanol as sole fluid source for 24 weeks. In alcohol-preferring animals (mean daily ethanol intake >5.0 g/kg) with free choice between ethanol and water, single intraperitoneal Selank injection (0.3 mg/kg) eliminated withdrawal-induced anxiety in elevated plus maze and social interaction tests and prevented mechanical allodynia formation without affecting ethanol consumption. Findings suggested Selank effectively eliminates alcohol withdrawal symptoms in rats, supporting potential therapeutic applications in managing acute withdrawal phases during alcohol dependence treatment without interfering with voluntary consumption patterns or substituting for alcohol's rewarding effects.

This study examined GABA, Selank, olanzapine, and their combinations' effects on GABAergic system gene expression in neuroblastoma IMR-32 cells using qPCR. Selank alone produced no mRNA level changes in 84 studied genes. Combined GABA and Selank nearly completely suppressed GABA-induced gene expression changes. Selank with olanzapine produced more gene expression alterations than olanzapine alone. GSEA analysis revealed Selank-olanzapine combination affected gamma-aminobutyric acid signaling pathway genes where BDNF played central role. Results indicated Selank lacks direct GABAergic gene effects but modulates GABA-GABA-A receptor interactions and enhances olanzapine effects, supporting allosteric modulation hypothesis. Gene expression patterns suggested complex multi-target mechanisms underlying Selank's pharmacological profile.

This foundational study demonstrated intranasal Selank administration regulates BDNF gene expression and metabolism in rat hippocampus in vivo. Using immunoenzyme techniques and mRNA analysis, researchers showed Selank rapidly influenced BDNF levels in hippocampal tissue—a brain region critical for learning, memory consolidation, and emotional regulation. The intranasal administration route proved optimal for peptide CNS delivery, avoiding first-pass metabolism and achieving direct brain tissue effects. BDNF regulation represented a key molecular mechanism underlying Selank's cognitive-enhancing and neuroprotective properties observed in behavioral studies. This work established the neurotrophin modulation pathway as central to Selank's multi-faceted therapeutic effects beyond simple anxiolytic action.